TAMPA, FL– Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) is acquiring DNAPrint Genomics.

Financial details were not disclosed.

Nanobac says with the acquisition it becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development.

Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics.

DNAPrint Genomics has developed, patented and published various technologies for an improved, 21st century model of clinical product development – aimed at maximizing effectiveness, minimizing unintended effects, reducing costs and shifting the risk to reward ratio during clinical product development.

he combined company would have annualized revenue of approximately $5 million, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.

On the Web: www.nanobac.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2008, TechJournal South. All rights reserved.